Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.
Exact Sciences Corp (NASDAQ: EXAS) is frequently in the news as a leading provider of cancer screening and diagnostic tests. Company announcements highlight developments across stool-based colorectal cancer screening, multi-cancer early detection, liver cancer surveillance, and precision oncology genomics. News coverage often reflects new clinical data, product launches, collaborations, and corporate transactions that shape the company’s role in cancer diagnostics.
Investors and clinicians following EXAS news can expect updates on the performance and adoption of the Cologuard and Cologuard Plus colorectal cancer screening tests, including real‑world adherence data and modeling studies that examine benefit‑to‑burden trade‑offs. Exact Sciences also reports on progress with its Cancerguard multi‑cancer early detection blood test, including study results from large prospective trials designed to support broader clinical use.
Another recurring theme in Exact Sciences news is the expansion of its precision oncology and surveillance portfolio. Releases describe pivotal and prospective studies of the Oncoguard Liver blood test for hepatocellular carcinoma surveillance, the Oncodetect molecular residual disease test in high‑risk breast cancer and other solid tumors, and the OncoExTra comprehensive genomic profiling assay for advanced cancers. These updates often come from major scientific meetings and include details on sensitivity, specificity, and prognostic performance.
Corporate and financial news items for EXAS include quarterly earnings releases, updated revenue and adjusted EBITDA guidance, participation in investor conferences, and strategic agreements such as the collaboration and license arrangement with Freenome for blood‑based colorectal cancer screening tests. A notable development disclosed in both press releases and SEC filings is the definitive agreement under which Abbott Laboratories plans to acquire Exact Sciences, subject to stockholder and regulatory approvals and other customary conditions.
This news page aggregates such announcements, offering a single place to review Exact Sciences’ latest clinical, product, financial, and transaction-related updates over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Exact Sciences (NASDAQ: EXAS) announced advancements in cancer detection at the AACR Annual Meeting 2023 in Orlando, Florida, from April 14-19. The company emphasizes the efficiency of advanced imaging after a positive multi-cancer early detection (MCED) test for identifying tumor locations. Preliminary findings suggest potential for molecular residual disease (MRD) detection technologies in monitoring cancer recurrence post-therapy. Key presentations include data showing fewer diagnostic procedures needed with advanced imaging compared to molecular testing, and promising results from tumor-informed MRD methodologies in distinguishing cancer samples. The developments could enhance early detection strategies and improve treatment decision-making for patients.
Exact Sciences Corp. (NASDAQ: EXAS) announced it will release its Q1 2023 financial results on May 9, 2023, after U.S. financial markets close. A conference call and webcast will follow at 5 p.m. ET to discuss the results and business developments. Exact Sciences, a leader in cancer screening and diagnostics, is known for its innovative products like Cologuard® and Oncotype®. The company continues to invest in its product pipeline to enhance patient care before and during cancer treatment.
For details, join the webcast at www.exactsciences.com or dial in at 888-330-2384 (domestic) and +1 240-789-2701 (international).
Exact Sciences Corp. (Nasdaq: EXAS) announced a transaction on February 23, 2023, involving the exchange of $500 million in new 2.00% Convertible Senior Notes due March 1, 2030, for existing convertible notes totaling approximately $384 million and $138 million in cash. The transaction is set to close on March 1, 2023. The new notes will have a semi-annual interest payment structure and can be converted into shares of common stock or cash, beginning September 1, 2023. The initial conversion price is about $80.83 per share, indicating a 25% premium over the previous closing price of $64.66.
Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer screening, announced its participation in key investor conferences in March 2023. The company will host fireside chats at:
- Citi's Healthcare Services Conference on March 1 at 2:45 p.m. ET in New York.
- Cowen Health Care Conference on March 6 at 10:30 a.m. ET in Boston.
- Raymond James Institutional Investors Conference on March 7 at 4:00 p.m. ET in Orlando.
Investors can access webcasts of the presentations on the Exact Sciences website. The company focuses on innovative cancer diagnostic solutions and is dedicated to improving patient outcomes.
Exact Sciences Corp. (Nasdaq: EXAS) reported a record fourth-quarter revenue of $553 million, marking a 17% increase, and $2,084 million for the full year 2022, an 18% increase. Excluding COVID-19 testing, fourth-quarter revenue grew by 28%. The company anticipates 2023 revenue between $2,265-$2,315 million. Notably, Screening revenue reached $404 million in Q4 2022, a 45% increase, while Precision Oncology revenue dropped 4% to $143 million. The net loss for the quarter was $127.7 million or $0.72 per share. Despite the losses, Exact Sciences reaffirmed its position with strong partnerships and innovative testing solutions.